Fig. 4
From: Efficacy and safety of aflibercept in in vitro and in vivo models of retinoblastoma
Suppressed Y-79 cell proliferation in the vitreous cavity after aflibercept treatment. As the tumor proliferated in the vitreous cavity, vitreous haziness became worse. 5 weeks after intravitreal injection of Y-79 cells, vitreous haziness which represented Y-79 cells proliferation was worse in the saline-injected group (n = 8), compared with that in the aflibercept treatment group (n = 14)